FDA Approves Brentuximab Vedotin with Lenalidomide and Rituximab for Relapsed or Refractory Large B-Cell Lymphoma By Ogkologos - March 27, 2025 693 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ECHELON-3 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Grants Traditional Approval to Selpercatinib for Locally Advanced or Metastatic RET Fusion-Positive Solid Tumours ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC MOST POPULAR Molecular Determinants of Sotorasib Efficacy in Patients with Advanced KRASG12C-mutated NSCLC June 6, 2025 New Research in Treating Leukemia and Lymphoma: ASH Annual Meeting 2020 January 15, 2021 Be a Holiday Helper! December 14, 2022 ¿Las gammagrafías óseas muestran el cáncer? April 28, 2021 Load more HOT NEWS A Combination of Nivolumab Plus Ipilimumab Prolongs PFS versus Nivolumab Alone... Mom Spots Strange Glow In Daughter’s Eye While Looking At Photo,... 5-Yr-Old Cancer Survivor Used His Birthday To Collect Toys For Sick... New 5-Minute Injection Reduces Time Breast Cancer Patients Spend in Treatment
